Sierra Oncology Inc. (SRRA)’s Financial Results Comparing With Translate Bio Inc. (NASDAQ:TBIO)

Both Sierra Oncology Inc. (NASDAQ:SRRA) and Translate Bio Inc. (NASDAQ:TBIO) are Biotechnology companies, competing one another. We will contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sierra Oncology Inc. N/A 0.00 49.65M -0.63 0.00
Translate Bio Inc. N/A 1399.78 108.27M -3.06 0.00

In table 1 we can see Sierra Oncology Inc. and Translate Bio Inc.’s gross revenue, earnings per share and valuation.


Table 2 hightlights the net margins, return on equity and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Sierra Oncology Inc. 0.00% -43.8% -40.8%
Translate Bio Inc. 0.00% 208.7% -52.9%


The Current Ratio of Sierra Oncology Inc. is 14.7 while its Quick Ratio stands at 14.7. The Current Ratio of rival Translate Bio Inc. is 16.7 and its Quick Ratio is has 16.7. Translate Bio Inc. is better equipped to clear short and long-term obligations than Sierra Oncology Inc.

Analyst Ratings

The table shown features the ratings and recommendations for Sierra Oncology Inc. and Translate Bio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sierra Oncology Inc. 0 0 0 0.00
Translate Bio Inc. 0 0 2 3.00

On the other hand, Translate Bio Inc.’s potential upside is 211.65% and its average price target is $23.

Institutional & Insider Ownership

Sierra Oncology Inc. and Translate Bio Inc. has shares held by institutional investors as follows: 63.4% and 49.9%. About 0.96% of Sierra Oncology Inc.’s share are held by insiders. Insiders Comparatively, held 19.6% of Translate Bio Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sierra Oncology Inc. -6.75% -8.98% -18.28% -52.35% -46.48% -59.25%
Translate Bio Inc. 17.7% 26.07% -26.26% 0% 0% -26.13%

For the past year Sierra Oncology Inc. was more bearish than Translate Bio Inc.


Translate Bio Inc. beats Sierra Oncology Inc. on 5 of the 8 factors.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.